Eli Lilly to Acquire Morphic Therapeutic for $3.2 Billion to Bolster IBD Pipeline with Oral Integrin Inhibitor MORF-057
Morphic Therapeutic
Oral Drug Manufacturers
Eli Lilly
Global Pharmaceutical R&D and Production Company
On July 8, 2024, Eli Lilly and Company announced an agreement to acquire all outstanding shares of Morphic Therapeutic, Inc. for A$57 per share in cash, for a total amount of approximately $3.2 billion. Through this acquisition,Eli Lilly will acquire Morphic Therapeutic's oral integrin therapy MORF-057 for the treatment of inflammatory bowel disease (IBD) and multiple autoimmune and oncology pipelines., thereby expanding its immunology product line. The transaction is expected to be completed in the third quarter of 2024.
On July 8, Eli Lilly and Company announced the acquisition of Morphic Therapeutic, an Australian biotech company.
In the first half of 2023, significant progress has been made in the research and development of autoimmune therapies targeting Integrin and TL1A. As interest in non-oncology fields continues to rise, multinational pharmaceutical companies are increasingly focusing onKey Points in the IBD FieldThe attention is also increasing:Since 2023, at least six major deals have been reached in the IBD field, involving pharmaceutical companies such as Merck, Roche, Sanofi, and AbbVie.This move by Eli Lilly and Company indicates that it is expanding its path in acquisitions, which also reflects, to a certain extent, the development strategies of multinational pharmaceutical companies.
TL1A(Tumor Necrosis Factor-Like Ligand 1A)AndIntegrinPlays an important role in inflammatory bowel disease (IBD). IBD mainly includes Crohn's Disease and Ulcerative Colitis, characterized by chronic inflammation of the intestines. TL1A is a cytokine of the TNF family that activates inflammatory signaling pathways by binding to its receptor DR3, promoting inflammatory responses in T cells and other immune cells, thereby exacerbating intestinal inflammation and damage. Studies have shown that TL1A is significantly elevated in the intestinal tissues of IBD patients; therefore, targeting TL1A is considered a potential therapeutic strategy for alleviating IBD symptoms.
2024 Morphic Therapeutic Drug Pipeline Progress
IntegrinThey are a class of cell surface adhesion molecules that participate in the interaction between cells and the extracellular matrix. In IBD, Integrins play a crucial role in leukocyte migration and inflammatory responses in intestinal tissues. For example,Integrin α4β7Through interaction with intestinal vascular endothelial cellsMAdCAM-1Combining, promotes the directional migration of leukocytes to the inflammatory site. Inhibiting Integrin activity can reduce the aggregation of leukocytes in the intestine, thereby alleviating the inflammatory response. In summary, TL1A and Integrin are two important molecular targets in the pathological process of IBD, and treatments targeting these two molecules are becoming a hotspot in research and clinical application, offering the hope of providing more effective treatment options for IBD patients.
Click the list to view Integrin recombinant proteins covering all 24 heterodimer subtypes
Click the list to learn about Integrin α4β7 Inhibitor Screening Kit information
Click the list to view Integrin ligand products
Click the list to view TL1A Native Trimer Recombinant Protein Products
Click the list to view TL1A report strains, overexpression strains products
Click the list to view DR3 recombinant protein products
To meet the development needs of IBD-related targeted Integrin antibody drugs, TL1A/DR3 antibody drugs, and TL1A agonists, ACROBiosystems has developed including:
Coverage24 Heterodimer Subtypes of Integrin Recombinant ProteinsAndIntegrin-related ligand protein: All are expressed by human-derived cells, validated by SEC-MALS, ELISA, SPR, and BLI, featuring high purity, high activity, and high batch-to-batch consistency. Suitable for applications such as immunization, antibody screening, and functional validation of candidate drugs.
Integrin α4β7 Inhibitor Screening Kit:A competitive ELISA method was used to establish an inhibitor screening platform, and a high-quality inhibitor screening kit was developed using a unique biotinylated protein, which can be used for preliminary screening and QC quality control release.
TL1A Recombinant Protein (Native Trimer Verified by Cell Assay)AndDR3 Recombinant Protein: All are expressed by human-derived cells, validated by SEC-MALS, ELISA, SPR, and BLI, featuring high purity, high activity, and high batch-to-batch consistency. Suitable for applications such as immunization, antibody screening, and functional validation of candidate drugs.
TL1A Reporter Gene Cell Line:Through receptor expression and functional activity validation, it can be applied to research on signaling functions of targeted agonist drugs, drug activity assays and screening at the cellular level, and drug CMC quality control release, among other applications. TL1A Overexpression Cell Line:Antigens are stably expressed on the surface of host cell membranes over the long term, meeting the needs for gene function research, immune/killing/proliferation validation, antibody drug activity screening (cell-level binding and blocking), and evaluation of CAR molecule killing activity.
ACROBiosystems conducts quality inspections on all products batch by batch, verifies performance such as purity and binding activity, and provides corresponding Protocols free of charge, which include the experimental operations and parameters of the R&D personnel, helping you save on the R&D cycle.
High Biological Activity of Integrin α4β7: Validated by ELISA
Activity (Bioactivity): ELISA
Immobilized Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ITGA4&ITGB7 Antibody, Human IgG4 with a linear range of 0.1-2 ng/mL (QC tested).
MAdCAM-1 High Purity: Validated by SDS-PAGE, SEC-MALS
Purity:Greater than 95% as verified by SDS-PAGE,Verified by SEC-MALS to be greater than 95%
The purity of Biotinylated Human MAdCAM-1, Fc Tag (Cat. No. MAM-H8251) is greater than 95% verified by SDS-PAGE and more than 95% verified by SEC-MALS.
TL1AProtein Activation Activity Validation - FOLD
Response to human TL1A protein (FOLD).
This reporter cell （Cat. No. SCJUR-STF178）was incubated with serial dilutions of human TL1A protein (Cat. No. TLA-H5243). The max induction fold was approximately 40.12.
DR3 High Bioactivity: Validated by SPR
Activity (Bioactivity): SPR
Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) immobilized on SA Chip can bind Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) with an affinity constant of 2.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested)
>> Click to learn more about inflammatory bowel disease drug development product information
>> Click to learn more about rheumatoid arthritis drug development product information
>> Click to learn more about Type I diabetes drug development product information
>> Click to learn more about autoimmune diseases and related product information
Scan to download:
Cell and Gene Therapy Drug Development and Evaluation Solutions
Scan to download:
Scan to download:
ACROBiosystems
inquiry@acrobiosystems.com
15117918562
(Note: Name + Company)